Home/Filings/4/0001144204-16-109554
4//SEC Filing

Caladrius Biosciences, Inc. 4

Accession 0001144204-16-109554

$LSTACIK 0000320017operating

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 5:56 PM ET

Size

9.6 KB

Accession

0001144204-16-109554

Insider Transaction Report

Form 4
Period: 2016-06-22
Wei Eric
Director
Transactions
  • Award

    Options to Purchase Common Stock

    2016-06-22+12,50012,500 total
    Exercise: $0.52From: 2017-06-22Exp: 2026-06-22Common Stock (12,500 underlying)
  • Award

    Common Stock

    2016-06-22+7,50026,500 total
Holdings
  • Common Stock

    (indirect: See Footnote)
    1,987,426
Footnotes (4)
  • [F1]Represents 7,500 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017.
  • [F2]Includes 9,000 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 25, 2017 and 7,500 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017.
  • [F3]1,975,426 shares of Common Stock of the Issuer are held by RimAsia Capital Partners L.P., a Cayman Islands exempted limited partnership ("RimAsia LP"), and 12,000 shares of Common Stock of the Issuer are held by RimAsia Capital Partners Manager, Ltd., a Cayman Islands exempted company ("RimAsia Manager").
  • [F4]RimAsia Capital Partners GP, L.P., a Cayman Islands exempted limited partnership ("RimAsia GP"), is the general partner of RimAsia LP. RimAsia Manager is the Fund Manager of RimAsia GP and the Manager of RimAsia LP. Mr. Wei is the managing partner of RimAsia LP, an indirect partner of RimAsia GP, a director of RimAsia Capital Partners GP, Ltd. and a director of RimAsia Manager. As a result, Mr. Wei may be deemed to have sole power to vote certain of the securities held by RimAsia LP and RimAsia Manager. Mr. Wei disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Securities Exchange Act or for any other purpose.

Issuer

Caladrius Biosciences, Inc.

CIK 0000320017

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000320017

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 5:56 PM ET
Size
9.6 KB